Novo Nordisk A/S Announces Results from Tresiba Study
Novo Nordisk A/S announced that it presented a study showing that Tresiba patients have a better health-related quality of life compared to patients on insulin Lantus from Sanofi French. There is a better physical health, partly because Tresiba-patients receive fewer cases of low blood sugar, but also because patients had statistically significant benefits in relation to exercise capacity, such as the ability to go and get dressed, and experienced less physical pain. The data comes from a one-year extension study, which together with the original study gives data from two years of trials. The overall results are based on 659 patients who completed the extension study, including 505 Tresiba patients and 154 Lantus patients.
Latest Developments for Novo Nordisk A/S
- FSA reports Novo Nordisk A/S to police for violating disclosure obligations-Reuters
- Committee for Medicinal Products for Human Use Adopts Positive Opinion on NovoRapid PumpCart Developed in Partnership between Novo Nordisk A/S and Roche Diabetes Care
- Novo Nordisk A/S' NovoEight Passes Review by Committee on Drugs of Pharmaceutical Affairs in Japan
- Novo Nordisk A/S Gets FDA Approval for Medic Pen in United States-DJ
Latest Key Developments in Pharmaceuticals
- Plethora Solutions Holdings PLC announces CEO Appointment
- Merck & Co Inc announces launch of new business focused on weight management interventions in U.S.
- Coronado Biosciences Inc announces management changes
- Auxilium Pharmaceuticals Inc submits application to the FDA requesting approval of xiaflex for concurrent treatment of multiple palpable cords
- Share this
- Digg this